Appointment

Alliance Pharma PLC
08 June 2006


For Immediate Release                                      8 June 2006


                              ALLIANCE PHARMA PLC
                      ('Alliance Pharma' or 'the Company')

                     Appointment of Non-Executive Director


Alliance Pharma plc (AIM: APH), a speciality pharmaceutical company, is pleased
to announce that it has appointed Andrew Leonard Smith, a highly experienced
healthcare executive, as a Non-Executive Director of the Company.


Mr Smith, aged 56, has international experience of the pharmaceutical,
biotechnology and  medico-marketing services industries gained at companies
including SmithKline Beecham plc, Cerebrus plc and Parexel International. He is
currently a consultant with the partnership Navitas BioPharma Consulting, which
focuses on small to medium sized companies in biotechnology and pharmaceuticals.



Between 1987 and 1996, Mr Smith worked in a number of marketing and managerial
roles at SmithKline Beecham (now GlaxoSmithKline plc) including Managing
Director and Senior Vice President of SmithKline Beecham Pharmaceuticals UK &
Ireland and Chairman of Diversified Health Systems Europe.


Mr Smith was Chief Executive Officer of UK biotechnology company Cerebrus plc
between 1996 and 1999 and, after Cerebrus was acquired by Vanguard Medica plc
(now Vernalis plc) he moved to Boston, MA, to take the position of President of
Parexel International's Medical Marketing Services Business.


Michael Gatenby, Alliance Pharma's Chairman, said: 'I am delighted to welcome
Andrew to Alliance Pharma's Board. His considerable experience gained across the
pharmaceutical industry will be of significant value to the Company in its
future development, particularly in the commercialisation of our key
developments of Posidorm and Isprelor.'



Directorships held by Andrew Smith in the past five years:

Rosemont Pharmaceuticals Ltd
Parexel International Corp Inc


There are no further disclosures to be made in accordance with Schedule 2 (g) of
the AIM rules.


For further information:


Alliance Pharma plc                                     + 44 (0) 1249 466966

John Dawson, Chief Executive
Maddy Scott, Finance Director
www.alliancepharma.co.uk

Buchanan Communications                                 + 44 (0) 20 7466 5000
Mark Court/Lisa Baderoon/Rebecca Dietrich




Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceutical
company based in Chippenham, Wiltshire, UK. The company has a strong track
record of acquiring the rights to established niche brands and owns, or shares,
the rights to 30 branded pharmaceutical products and continues to explore
opportunities to expand the range.



Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the
prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven.  Its products are
distributed to hospitals directly and to UK and International pharmaceutical
wholesalers which service both hospital and retail pharmacies with their
prescription requirements.



Alliance Pharma is also developing Posidorm for sleep disorders and Isprelor for
the induction of labour.



Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.


--------------------------






                      This information is provided by RNS
            The company news service from the London Stock Exchange